The latest price target for RenovoRx (NASDAQ:RNXT) was reported by Ascendiant Capital on September 12, 2024. The analyst firm set a price target for $8.25 expecting RNXT to rise to within 12 months (a possible 560.79% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for RenovoRx (NASDAQ:RNXT) was provided by Ascendiant Capital, and RenovoRx maintained their buy rating.

There is no last upgrade for RenovoRx

The last downgrade for RenovoRx Inc happened on November 15, 2023 when Maxim Group changed their price target from N/A to N/A for RenovoRx Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RenovoRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RenovoRx was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

While ratings are subjective and will change, the latest RenovoRx (RNXT) rating was a maintained with a price target of $8.00 to $8.25. The current price RenovoRx (RNXT) is trading at is $1.25, which is out of the analyst’s predicted range.